1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nexsen Limited

Nexsen Limited

NXN.AX
Nexsen LimitedAU flagAustralian Securities Exchange
0.13
AUD
+0.02
- -
26.26MMarket Cap
Nexsen Limited
NXN.AX
(Australian Securities Exchange)

Recent

price

0.13

P/E

ratio

- -

div

yld

- -

ROIC.AI

2025
2026
FRC
- -
- -
Revenue per Share
- -
-0.04
Basic EPS, GAAP
- -
- -
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
- -
0.03
Book Value per Share
- -
0.02
Tangible Book Value per Share
200
180
Basic Weighted Avg Shares
- -
- -
Sales/Revenue/Turnover
- -
- -
Operating Margin (%)
- -
- -
Depreciation Expense
- -
-7
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
- -
4
Working Capital
- -
- -
LT Debt
- -
6
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
-231.53
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
-0.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Asymchem Laboratories (Tianjin) Co., Ltd. (6821.HK)
Jyong Biotech Ltd. Ordinary Shares (MENS)
Biora Therapeutics, Inc. (BIORQ)
IXICO plc (IXI.L)
Verde Science, Inc. (VRCI)
NanoViricides, Inc. (NNVC)
Business
Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. The company was incorporated in 2021 and is based in Sydney, Australia.